Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PB101

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Panolos Biosci

Drug class:

VEGF-A inhibitor, Angiogenesis inhibitor, PIGF inhibitor, VEGF-B inhibitor

Related drugs:

‹

84AA-API 14AA (0)

sonepcizumab (0)

bevacizumab (416)

Aybintio (bevacizumab biosimilar) (14)

bevacizumab-maly (12)

bevacizumab-awwb (11)

bevacizumab-adcd (11)

bevacizumab-tnjn (8)

bevacizumab-bvzr (8)

Krabeva (bevacizumab biosimilar) (7)

Byvasda (bevacizumab biosimilar) (4)

ziv-aflibercept IV (4)

SIBP-04 (bevacizumab biosimilar) (1)

BP102 (bevacizumab biosimilar) (0)

SCT510 (bevacizumab biosimilar) (0)

Ankada (bevacizumab biosimilar) (0)

BI 695502 (bevacizumab biosimilar) (0)

MIL 60 (bevacizumab biosimilar) (0)

LY01008 (bevacizumab biosimilar) (0)

CBT124 (bevacizumab biosimilar) (0)

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

defibrotide (0)

84AA-API 14AA (0)

sonepcizumab (0)

›